Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy

Liu, Ning; Zhang, Renshuai; Shi, Qiang; Jiang, Hongfei; Zhou, Qihui

doi:10.1016/j.bioorg.2023.106550

Cited by 17 publications

(6 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were consistent with PDT. Ce6 rapidly produced ROS under 660 nm laser irradiation, interacted with biomolecules in cancer cells, destroyed its structure, and eventually led to tumor cell death. , …”

Section: Resultsmentioning

confidence: 99%

“…The observed phenomena can be attributed to several factors. First, Ce6 photosensitizer produces ROS under 660 nm laser irradiation, which causes damage to cell membrane, mitochondria, and so forth, and cooperates with PTX-induced tumor cell death. ,, Second, Ce6 accelerated the cleavage of the conjugated double bond of the polymer PEG-OE-L, thereby increasing the release of PTX and Ce6 in liposomes. In addition, Dr-lips improved the solubility, cell uptake, and overall drug efficacy of Ce6.…”

Section: Resultsmentioning

confidence: 99%

“…Ce6 rapidly produced ROS under 660 nm laser irradiation, interacted with biomolecules in cancer cells, destroyed its structure, and eventually led to tumor cell death. 40,52 In Figure 6E, the IC50 values of Ce6 + PTX/Dr-lips and free PTX in the absence of light were 1.950 and 1.914, respectively, indicating that drug-loaded liposomes could effectively deliver laser irradiation. Cell live dead staining experiments confirmed these findings (Figure 7).…”

Section: Characterization Of Liposomesmentioning

confidence: 95%

See 2 more Smart Citations

Lutein-Based pH and Photo Dual-Responsive Novel Liposomes Coated with Ce6 and PTX for Tumor Therapy

Shen,

Zhang,

Wang

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Liposomes are considered the best nanocarrier for delivering cancer drugs such as chlorin e6 (Ce6) and paclitaxel (PTX). However, the poor stability and non-selectivity release of liposomes may severely limit their further applications. In this study, based on the characteristics of lutein (L) photo-response and orthoester (OE) acid-response, stable and dual-responsive liposomes (Dr-lips) have been prepared. The Dr-lips exhibited a spherical shape with a uniform size of approximately 58.27 nm. Moreover, they displayed a zeta potential ranging from −45.45 to −28.25 mV and showed excellent storage stability, indicating stable colloidal properties. Additionally, they achieved high drug encapsulation rates, with 92.27% for PTX and 90.34% for Ce6, respectively. Meanwhile, under near-infrared (NIR) light at 660 nm, Ce6 plays a key role in accelerating the photodegradation rate of lutein and PEG-OE-L while also enhancing tissue penetration ability. Additionally, Dr-lips loaded with Ce6 and PTX not only displayed excellent pH and photo dual-responsiveness for targeted delivering and releasing but also showed remarkable reactive oxygen species (ROS) generation capacity and impressive anti-tumor activity in vitro. Therefore, it provides a novel strategy for optimizing stability and enhancing their targeted drug delivery of liposome.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Characterization Of Liposomesmentioning

confidence: 95%

See 1 more Smart Citation

Lutein-Based pH and Photo Dual-Responsive Novel Liposomes Coated with Ce6 and PTX for Tumor Therapy

Shen,

Zhang,

Wang

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…While immunotherapy continues to show promise in the field of cancer research, it is not without clinical limitations. Despite the successes of some clinical drugs targeting immunotherapy in long-term treatment, drug resistance frequently occurs, and resistance mechanisms are complex [ 37 , 38 ], making present clinical solutions suboptimal. Thus, comprehensively exploring and elucidating the mechanisms of drug resistance remains a major challenge for current cancer treatment.…”

Section: Current Status Of Cancer Researchmentioning

confidence: 99%

Empagliflozin: a potential anticancer drug

Wang

Xie

et al. 2023

Discov Onc

View full text Add to dashboard Cite

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective. It also has anti-inflammatory and antioxidative stress effects in diabetic nephropathy. Several studies have shown that empagliflozin has anticancer effects. SGLT2 is expressed in a variety of cancer cell lines. The SGLT2 inhibitor empagliflozin has significant inhibitory effects on certain types of tumor cells, such as inhibition of proliferation, migration and induction of apoptosis. In conclusion, empagliflozin has promising applications in cancer therapy as a drug for the treatment of diabetes and heart failure. This article provides a brief review of the anticancer effects of empagliflozin.

show abstract

“…21 Additionally, the utilization of various stimuli-responsive linkages within intelligent prodrugs has become a trend. 22,23 In view of this, specific tumor-responsive prodrugs can dramatically decrease toxicity against normal cells while maintaining the toxicity against tumor tissues. 24 In the past twenty years, prodrug nanomedicines have been extensively explored for cancer therapy.…”

Section: Introductionmentioning

confidence: 99%